Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
1.
Braz. j. med. biol. res ; 45(4): 357-365, Apr. 2012. tab
Article Dans Anglais | LILACS | ID: lil-622757

Résumé

This paper presents an up-to-date review of the evidence indicating that atypical neurotransmitters such as nitric oxide (NO) and endocannabinoids (eCBs) play an important role in the regulation of aversive responses in the periaqueductal gray (PAG). Among the results supporting this role, several studies have shown that inhibitors of neuronal NO synthase or cannabinoid receptor type 1 (CB1) receptor agonists cause clear anxiolytic responses when injected into this region. The nitrergic and eCB systems can regulate the activity of classical neurotransmitters such as glutamate and γ-aminobutyric acid (GABA) that control PAG activity. We propose that they exert a ‘fine-tuning’ regulatory control of defensive responses in this area. This control, however, is probably complex, which may explain the usually bell-shaped dose-response curves observed with drugs that act on NO- or CB1-mediated neurotransmission. Even if the mechanisms responsible for this complex interaction are still poorly understood, they are beginning to be recognized. For example, activation of transient receptor potential vanilloid type-1 channel (TRPV1) receptors by anandamide seems to counteract the anxiolytic effects induced by CB1 receptor activation caused by this compound. Further studies, however, are needed to identify other mechanisms responsible for this fine-tuning effect.


Sujets)
Animaux , Souris , Rats , Anxiété/physiopathologie , Réaction de fuite/physiologie , Agents neuromédiateurs/physiologie , Substance grise centrale du mésencéphale/physiologie , Transmission synaptique/physiologie , Anxiété/métabolisme , Acides arachidoniques/pharmacologie , Agonistes des récepteurs de cannabinoïdes/pharmacologie , Endocannabinoïdes/pharmacologie , Endocannabinoïdes/physiologie , Monoxyde d'azote/physiologie , Substance grise centrale du mésencéphale/métabolisme , Amides gras polyinsaturés N-alkylés/pharmacologie , Canaux cationiques TRPV/physiologie
2.
Braz. j. med. biol. res ; 39(4): 421-429, Apr. 2006. ilus, tab, graf
Article Dans Anglais | LILACS | ID: lil-425087

Résumé

A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The antipsychotic-like properties of CBD have been investigated in animal models using behavioral and neurochemical techniques which suggested that CBD has a pharmacological profile similar to that of atypical antipsychotic drugs. The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD. In addition, open case reports of schizophrenic patients treated with CBD and a preliminary report of a controlled clinical trial comparing CBD with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia. Future studies of CBD in other psychotic conditions such as bipolar disorder and comparative studies of its antipsychotic effects with those produced by clozapine in schizophrenic patients are clearly indicated.


Sujets)
Animaux , Humains , Souris , Rats , Anxiolytiques/usage thérapeutique , Neuroleptiques/usage thérapeutique , Cannabidiol/usage thérapeutique , Cannabis/composition chimique , Schizophrénie/traitement médicamenteux , Essais cliniques comme sujet , Modèles animaux de maladie humaine , Troubles mentaux/induit chimiquement , Troubles mentaux/traitement médicamenteux
3.
Arq. bras. cardiol ; 38(2): 125-9, 1982.
Article Dans Portugais | LILACS | ID: lil-8773

Résumé

E relatado o caso de paciente do sexo feminino, de 33 anos, com dados clinicos sugestivos de dupla lesao mitral.O estudo ecocardiografico e angiocardiografico fizeram o diagnostico de mixoma do atrio esquerdo. A tomografia computadorizada foi realizada demonstrando claramente o tumor.A paciente foi operada e o mixoma ressecado com sucesso.Sao discutidos aspectos referentes a localizacao e fisiopatologia desse tipo de afeccao, com enfase no valor da tomografia computadorizada no seu estudo


Sujets)
Humains , Femelle , Adulte , Tomodensitométrie , Myxome , Tumeurs du coeur , Atrium du coeur
SÉLECTION CITATIONS
Détails de la recherche